ORAMED PHARMACEUTICALS INC. financial data

Symbol
ORMP on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2429% % 266%
Return On Equity 27% % 1020%
Return On Assets 26% % 1128%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39,802,455 shares -1.3%
Common Stock, Shares, Outstanding 40,838,226 shares 1.6%
Entity Public Float $131,190,607 USD 0.51%
Common Stock, Value, Issued $490,000 USD 1.2%
Weighted Average Number of Shares Outstanding, Basic 41,756,301 shares 2.1%
Weighted Average Number of Shares Outstanding, Diluted 42,774,504 shares 4.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $2,000,000 USD
Cost of Revenue $1,987,000 USD
Research and Development Expense $5,854,000 USD -12%
General and Administrative Expense $7,170,000 USD 11%
Operating Income (Loss) $13,011,000 USD 0.4%
Nonoperating Income (Expense) $68,090,000 USD 206%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $55,744,000 USD
Income Tax Expense (Benefit) $11,062,000 USD 876%
Net Income (Loss) Attributable to Parent $43,809,000 USD 988%
Earnings Per Share, Basic 1 USD/shares 836%
Earnings Per Share, Diluted 0 USD/shares 800%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $52,179,000 USD
Marketable Securities, Current $4,956,000 USD 667%
Assets, Current $136,117,000 USD -4.7%
Other Long-term Investments $7,155,000 USD
Property, Plant and Equipment, Net $614,000 USD -14%
Operating Lease, Right-of-Use Asset $817,000 USD 68%
Other Assets, Noncurrent $40,000 USD
Assets $220,493,000 USD 34%
Accounts Payable, Current $560,000 USD
Employee-related Liabilities, Current $233,000 USD
Accrued Liabilities, Current $585,000 USD
Liabilities, Current $6,119,000 USD 16%
Contract with Customer, Liability, Noncurrent $2,000,000 USD -50%
Deferred Income Tax Liabilities, Net $7,921,000 USD
Operating Lease, Liability, Noncurrent $589,000 USD 217%
Other Liabilities, Noncurrent $60,000 USD -4.8%
Retained Earnings (Accumulated Deficit) $122,575,000 USD 26%
Stockholders' Equity Attributable to Parent $203,282,000 USD 30%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $202,330,000 USD 30%
Liabilities and Equity $220,493,000 USD 34%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,519,000 USD -138%
Net Cash Provided by (Used in) Financing Activities $19,000,000 USD -882%
Net Cash Provided by (Used in) Investing Activities $23,616,000 USD -21%
Common Stock, Shares Authorized 60,000,000 shares 0%
Common Stock, Shares, Issued 40,838,226 shares 1.6%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $20,096,000 USD 111%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $52,179,000 USD 24%
Interest Paid, Excluding Capitalized Interest, Operating Activities $571,000 USD
Deferred Tax Assets, Valuation Allowance $36,120,000 USD 27%
Operating Lease, Liability $860,000 USD 100%
Depreciation $30,000 USD -46%
Payments to Acquire Property, Plant, and Equipment $3,000 USD 50%
Lessee, Operating Lease, Liability, to be Paid $880,000 USD 98%
Operating Lease, Liability, Current $271,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year Two $162,000 USD 17%
Lessee, Operating Lease, Liability, to be Paid, Year One $295,000 USD 33%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $20,000 USD 25%
Lessee, Operating Lease, Liability, to be Paid, Year Three $134,000 USD 644%
Deferred Tax Assets, Operating Loss Carryforwards $26,797,000 USD -3.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four $129,000 USD
Interest Expense $592,000 USD